Full-Time

Associate Director

Technical Product Management

Posted on 4/11/2026

Deadline 4/24/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$142.4k - $224.1k/yr

+ Annual Bonus + Long-Term Incentive

No H1B Sponsorship

North Wales, PA, USA

Hybrid

Hybrid work model: three days on-site per week; Friday remote; days may vary by site.

Bachelor's

Category
Product (1)
Required Skills
Veeva
Python
GitHub Actions
Product Management
Workday HRIS
ETL
SAP Products
Salesforce
AWS
Terraform
Ansible
REST APIs
DevOps

Get referred to Merck

See people who can refer or advise you

Requirements
  • Bachelor's degree or equivalent in Computer Engineering, Computer Science, Computer Applications, or a closely related field and 8 years of experience in the position offered or related.
  • Requires 5 years of experience with all of the following: experience across software engineering lifecycle, including planning, design of ETL solutions, coding, debugging, testing, and architecture standards definition.
  • Working with distributed teams; facilitation, marketing and persuasion skills; and communicating technical concepts to non-technical stakeholders.
  • Data integration and modeling technologies, with strong proficiency in Intelligent Data Management Cloud (IDMC) and iPaaS, as well as extensive data integration experience with enterprise applications such as Workday, Salesforce, Veeva and SAP.
  • Designing, configuring, and managing data platform using DevSecOps tools such as Terraform, Github Actions, Ansible and Python, with experience in AWS architecture and its services – inclusive of EC2, EFS, FSx, Lambda, S3 and orchestration services and analytical databases.
  • Developing and delivering digital products and services leading cross-functional teams with large portion in life sciences domain.
  • Stakeholder management skills; conducting market analysis and user research.
  • Domain expertise in life sciences and pharmaceutical manufacturing.
  • Building and provisioning engineering toolsets with high autonomy, automation, and self-service level; advising clients on related solutions and services; experience with ETL technologies and Cloud Databases.
  • Designing and building self service capabilities in the integration platform, automating deployments and workspace provisioning.
Responsibilities
  • Collaborate with CTO leaders and other API and Integration leads to identify the API and integration needs across the enterprise and help solve for these needs.
  • Partner with other foundational platforms teams, enterprise architecture, networking and cloud computing and other teams to architect, design, implement digital services and products, as well as drive their adoption in (not only) divisional teams.
  • Maximize value of the product across full lifecycle (from start to decommissioning where applicable).
  • Drive optimization of TCO and ROI realization across the products and solutions.
  • Develop business case(s) and investment plans in support of investments in the product, gain investment approvals and monitor and manage spend and ROI for the investments.
  • Prioritize backlogs, roadmaps, identify and mitigate dependencies.
  • Drive execution & successful delivery towards set OKRs. Lead (manage) global vendor relationships and cross-functional global agile teams implementing platforms or solutions (no direct reports).
  • Engage with key stakeholders and API and integration area owners across the enterprise to understand the capability needs in this area, and support these needs and address them at resilient, core-service level. In collaboration with Enterprise Architecture and other teams, define API & Integration technology and governance standards relevant to the product and customize them to domains or locations where necessary.
  • Plan and execute on transitioning services and projects to products where applicable.
  • Engage with external partners and thought leaders to keep abreast of latest technology and trends in the API & Integration domain.
  • Leverage this external perspective to influence the product and services and enable innovation to support IT teams’ API and integration needs.
  • Develop and implement communications and marketing strategies to ensure awareness and education of the product.
  • Monitor and enhance adoption and usage of the product and digital services.
  • Build, grow and support the talent in the global team.
  • Up to 10% international travel required.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.6 billion; management raised full-year guidance to $66.3-$67.3 billion.
  • Keytruda QLEX generated $463 million in Q2 2026, cushioning future intravenous Keytruda erosion.
  • SCRI partnership broadens oncology trial access across 200 community sites, accelerating enrollment.

What critics are saying

  • Gardasil weakness triggered 150 North Carolina layoffs in February 2026 and continues pressuring vaccines.
  • The Terns deal created a $5.7 billion charge, crushing 2026 adjusted EPS to $2.66-$2.76.
  • Keytruda still dominates sales; a 2028-2029 patent cliff would hit Merck's core franchise.

What makes Merck unique

  • Keytruda family produced $8.4 billion in Q2 2026 across earlier- and metastatic cancers.
  • Merck stacked first-in-class perioperative bladder, kidney, and melanoma approvals during July-August 2026.
  • Animal Health adds durable diversification, with INNOVAX ND-IBD-ILT USDA approval August 13, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 19th, 2026
Moderna and Merck shares soar on breakthrough personalised mRNA cancer vaccine data

Moderna and Merck shares surged Wednesday after reporting positive Phase 3 results for their personalised mRNA cancer vaccine, intismeran autogene, combined with Merck's Keytruda. The trial met its primary endpoint in patients with stage IIB-IV melanoma. This marks the first positive Phase 3 readout for an individualised neoantigen therapy and mRNA-based cancer treatment. Moderna shares more than doubled intraday, whilst Merck jumped over 10%. The vaccine is individually manufactured using mutations from each patient's tumour and encodes up to 34 neoantigens. Earlier Phase 2b data showed the combination reduced recurrence or death risk by 49% compared with Keytruda alone. The companies plan to discuss regulatory submissions with authorities. Nine additional trials are underway across various cancer types, potentially validating Moderna's broader personalised cancer-vaccine platform.

Yahoo Finance
Aug 19th, 2026
Moderna and Merck melanoma vaccine cuts recurrence in late-stage trial

Moderna and Merck announced their personalised melanoma vaccine successfully reduced cancer recurrence in a large late-stage trial. The vaccine, combined with Merck's Keytruda immunotherapy, met its primary goal of reducing melanoma recurrences and slowing the cancer's spread. This marks the first positive final-stage trial for any mRNA-based cancer therapy. Moderna shares more than doubled in pre-market trading, whilst Merck rose as much as 9.5%. The companies will discuss regulatory approval and present detailed data at an upcoming medical meeting. Moderna CEO Stéphane Bancel said the product could be approved as soon as 2027. Melanoma affects roughly 112,000 Americans annually, with about 8,500 deaths per year. The vaccine, called intismeran autogene, is customised based on each patient's specific tumour mutations.

GeekWire
Aug 14th, 2026
InduPro raises $77M, begins first human trial of cancer drug.

InduPro raises $77M, begins first human trial of cancer drug. by John Cook on Aug 14, 2026 at 6:33 am InduPro, a 4-year-old biotech startup with operations in Seattle and Cambridge, Mass., this week announced $77 million in series B funding as it begins a Phase 1 clinical trial of its lead cancer drug candidate. The company said that the first patient has been dosed in the trial of IDP-001, an experimental antibody-drug conjugate designed to target cancer cells through a combination of two proteins on their surface. The early-stage trial is enrolling adults with advanced or metastatic non-small cell lung cancer and other solid tumors whose disease has progressed following standard treatment. Researchers will evaluate the drug's safety, tolerability, drug behavior and early signs of antitumor activity. InduPro is developing drugs based on the spatial relationships between proteins on the surface of cells. The company says its approach can identify combinations of targets that are close together on cancer cells but not on normal tissue, potentially allowing drugs to more selectively attack tumors. The Series B was led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi and Eli Lilly and Company. "We are delighted to have the support of this outstanding group of life sciences investors and strategic partners who recognize the potential of our proximity-guided platform to create precision therapeutics in oncology and autoimmune disease," said InduPro CEO Prakash Raman in a press release. Raman is a longtime biopharma executive who previously served as president and CEO of Ribon Therapeutics. Before that, he spent nearly 14 years at Novartis, where he served as vice president and global head of business development and licensing for the Novartis Institutes for Biomedical Research. The company's president and chief scientific officer is Scott Lesley, who previously served as vice president of discovery biologics at Merck. InduPro said the new funding will support the Phase 1 development of IDP-001 and further development of its preclinical pipeline, which includes programs targeting cancer and autoimmune diseases. Earlier this year, InduPro inked a strategic collaboration and licensing agreement with Eli Lilly covering up to three oncology targets, a deal worth up to approximately $950 million.

Yahoo
Aug 14th, 2026
SCRI and MSD to broaden US oncology trial access.

SCRI and MSD to broaden US oncology trial access. Salong Debbarma Updated Fri, August 14, 2026 at 2:46 AM PDT Sarah Cannon Research Institute (SCRI) and Merck & Co (MSD) have entered a collaboration aimed at increasing patient access to oncology clinical trials at community sites across the US. The partnership will utilise SCRI's Accelero delivery model, which is designed to improve both the reach and efficiency of cancer studies. MSD and SCRI are seeking to address the increasing complexity of oncology clinical studies, which require more precise patient selection and faster access to new therapies. The organisations aim to implement new approaches for trial delivery that are efficient, use advanced data methods, and can be integrated within local communities. MSD Research Laboratories associate vice-president and North America global clinical trial operations head Jennifer Coppola said: "At MSD, we are focused on advancing research to better understand cancer and potential therapeutic approaches. "By leveraging the Accelero delivery model, we have the potential to reach patients faster, reduce protocol complexity, and make oncology clinical studies more accessible in the communities where patients live." The Accelero model employed by SCRI includes accelerated trial site start-up, electronic data transfer systems connecting electronic health records (EHR) and case report forms, and initiatives to boost recruitment. Collaborations using Accelero have reported trial site activations up to 50% faster than conventional approaches, with enrolment rates 19% higher than the national average of 7%, and 95% fewer changes to data compared to standard processes. SCRI runs a network comprising around 1,500 oncology physicians, offering access to clinical studies at over 200 sites in more than 20 US states. The group reports involvement in over 900 first-in-human clinical trials since its formation. In October 2024, Exelixis and MSD partnered to assess the potential of combining their respective cancer therapies in upcoming trials. "SCRI and MSD to broaden US oncology trial access" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Yahoo Finance
Aug 12th, 2026
Merck Q2 revenue beats at $16.6B but lowers full-year EPS guidance by 47%

Merck reported second-quarter revenue of $16.61 billion, beating analyst estimates of $16.27 billion with 5.1% year-on-year growth. The pharmaceutical company's performance was driven by strong sales of KEYTRUDA in oncology and robust Animal Health results. The company raised its full-year revenue guidance to $66.8 billion at the midpoint but lowered adjusted earnings per share guidance to $2.71, a 46.9% decrease. Operating margin fell to -3.5% from 31.6% in the prior year, affected by higher operating expenses and acquisition-related charges. During the earnings call, analysts questioned management about planned clinical trials for pembrolizumab in first-line lung cancer, TL1A activity compared to TNF inhibitors, and commercial adoption expectations for LIPFENDRA. CEO Robert Davis highlighted expansion opportunities for oral PCSK9 treatments in primary care markets.

INACTIVE